COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence?
Top Cited Papers
Open Access
- 12 May 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 323 (18), 1769-1770
- https://doi.org/10.1001/jama.2020.4812
Abstract
This Viewpoint reviews the pathophysiological and observational basis for speculating that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) might worsen clinical outcomes for patients with COVID-19, and summarizes guidance from specialty societies to continue the drugs in patients who need them pending more definitive evidence of harm.This publication has 7 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromeCritical Care, 2017
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolismBiochemical Journal, 2004